Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
29
TNXP Quote, Financials, Valuation and Earnings
Last price:
$17.13
Seasonality move
:
2.21%
Day range:
$17.03 - $18.63
52-week range:
$6.76 - $69.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.21x
P/B ratio:
0.54x
Volume:
1M
Avg. volume:
719K
1-year change:
-70.02%
Market cap:
$125.7M
Revenue:
$10.1M
EPS (TTM):
-$986.99
Analysts' Opinion
-
Consensus RatingTonix Pharmaceuticals Holding Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $66.33, Tonix Pharmaceuticals Holding Corp. has an estimated upside of 288.14% from its current price of $17.09.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $64.00 representing 100% downside risk from its current price of $17.09.
Fair Value
-
According to the consensus of 2 analysts, Tonix Pharmaceuticals Holding Corp. has 288.14% upside to fair value with a price target of $66.33 per share.
TNXP vs. S&P 500
-
Over the past 5 trading days, Tonix Pharmaceuticals Holding Corp. has underperformed the S&P 500 by -11.45% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Tonix Pharmaceuticals Holding Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Tonix Pharmaceuticals Holding Corp. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Tonix Pharmaceuticals Holding Corp. reported revenues of $3.3M.
Earnings Growth
-
Tonix Pharmaceuticals Holding Corp. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Tonix Pharmaceuticals Holding Corp. reported earnings per share of -$3.59.
Enterprise value:
-63.9M
EV / Invested capital:
--
Price / LTM sales:
9.21x
EV / EBIT:
--
EV / Revenue:
-6.20x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
0.81x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.6M
Return On Assets:
-55.71%
Net Income Margin (TTM):
-963.39%
Return On Equity:
-62.54%
Return On Invested Capital:
-61.13%
Operating Margin:
-1005.08%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $4M | $11.3M | $10.3M | $2.8M | $3.3M | |
| Gross Profit | -$2M | -$2.1M | $1.6M | $767K | $1.5M | |
| Operating Income | -$123.8M | -$82.6M | -$99.9M | -$15.6M | -$33.1M | |
| EBITDA | -$120.2M | -$78.2M | -$98M | -$15.1M | -$32.6M | |
| Diluted EPS | -$11.23 | -$20.56 | -$986.99 | -$0.23 | -$3.59 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $195.1M | $151.1M | $31.3M | $50.5M | $208.1M | |
| Total Assets | $214.8M | $242.6M | $139.3M | $95M | $252.4M | |
| Current Liabilities | $12M | $13.3M | $17.7M | $15.2M | $21M | |
| Total Liabilities | $12.6M | $13.7M | $18.4M | $20.8M | $21.3M | |
| Total Equity | $202.2M | $228.9M | $120.8M | $74.2M | $231.1M | |
| Total Debt | $530K | $382K | $716K | $5.6M | $266K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$104.4M | -$68.7M | -$77.3M | -$20M | -$30.5M | |
| Cash From Investing | -$34.4M | -$217.5K | -$3.7M | -$12.6K | -$1M | |
| Cash From Financing | $3.6M | $91.8M | $248.1M | $43.8M | $100.1M | |
| Free Cash Flow | -$117.1M | -$69.2M | -$78.9M | -$20M | -$31.5M | |
TNXP
Sector
Market Cap
$125.7M
$27.9M
Price % of 52-Week High
24.42%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-144.64%
-1.49%
1-Year Price Total Return
-70.02%
-16.66%
Beta (5-Year)
1.817
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$18.68
200-day SMA
Sell
Level
$26.98
Bollinger Bands (100)
Sell
Level
14.97 - 36.13
Chaikin Money Flow
Sell
Level
-1.4M
20-day SMA
Sell
Level
$17.61
Relative Strength Index (RSI14)
Sell
Level
43.41
ADX Line
Sell
Level
9.88
Williams %R
Neutral
Level
-63.5531
50-day SMA
Sell
Level
$18.01
MACD (12, 26)
Buy
Level
3.32
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Sell
Level
-1.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.3317)
Sell
CA Score
(Annual)
Level (-1.3995)
Buy
Beneish M-Score
(Annual)
Level (-5.1052)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (10.197)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.
Stock Forecast FAQ
In the current month, TNXP has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TNXP average analyst price target in the past 3 months is $66.33.
-
Where Will Tonix Pharmaceuticals Holding Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Tonix Pharmaceuticals Holding Corp. share price will rise to $66.33 per share over the next 12 months.
-
What Do Analysts Say About Tonix Pharmaceuticals Holding Corp.?
Analysts are divided on their view about Tonix Pharmaceuticals Holding Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Tonix Pharmaceuticals Holding Corp. is a Sell and believe this share price will drop from its current level to $64.00.
-
What Is Tonix Pharmaceuticals Holding Corp.'s Price Target?
The price target for Tonix Pharmaceuticals Holding Corp. over the next 1-year time period is forecast to be $66.33 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TNXP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Tonix Pharmaceuticals Holding Corp. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TNXP?
You can purchase shares of Tonix Pharmaceuticals Holding Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Tonix Pharmaceuticals Holding Corp. shares.
-
What Is The Tonix Pharmaceuticals Holding Corp. Share Price Today?
Tonix Pharmaceuticals Holding Corp. was last trading at $17.13 per share. This represents the most recent stock quote for Tonix Pharmaceuticals Holding Corp.. Yesterday, Tonix Pharmaceuticals Holding Corp. closed at $17.09 per share.
-
How To Buy Tonix Pharmaceuticals Holding Corp. Stock Online?
In order to purchase Tonix Pharmaceuticals Holding Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TNXP Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TNXP
Sector
P/E ratio
--
23.85x
PEG ratio
0.00x
-0.01x
P/B ratio
0.54x
1.81x
Price / LTM sales
9.21x
1.58x
Growth Metrics
TNXP
Sector
Revenue growth
16.58%
4.62%
Earnings growth
-1467.92%
10.5%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$2.75
-$0.21
Profitability
TNXP
Sector
Profitability FY 2024
-$1.1M
$3.6M
Return on invested capital
-61.13%
-31.87%
Return on assets
-55.71%
-28.18%
Return on equity
-62.54%
-37.63%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
17
Estimated Next Earnings Date
Feb
9
Balance Sheet
TNXP
Sector
Total cash
$190.1M
$26.4M
Short term investments
--
$25.7M
Total assets
$162.9M
$76.9M
Long term debt
$266K
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
